Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program. The alliance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback